122 related articles for article (PubMed ID: 28088073)
1. Strategies to design clinical studies to identify predictive biomarkers in cancer research.
Perez-Gracia JL; Sanmamed MF; Bosch A; Patiño-Garcia A; Schalper KA; Segura V; Bellmunt J; Tabernero J; Sweeney CJ; Choueiri TK; Martín M; Fusco JP; Rodriguez-Ruiz ME; Calvo A; Prior C; Paz-Ares L; Pio R; Gonzalez-Billalabeitia E; Gonzalez Hernandez A; Páez D; Piulats JM; Gurpide A; Andueza M; de Velasco G; Pazo R; Grande E; Nicolas P; Abad-Santos F; Garcia-Donas J; Castellano D; Pajares MJ; Suarez C; Colomer R; Montuenga LM; Melero I
Cancer Treat Rev; 2017 Feb; 53():79-97. PubMed ID: 28088073
[TBL] [Abstract][Full Text] [Related]
2. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
3. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
4. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
Bertagnolli MM
J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
[No Abstract] [Full Text] [Related]
5. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
Hawkes E; Cunningham D
J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
[No Abstract] [Full Text] [Related]
6. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
7. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
8. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
Wong R; Cunningham D
J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
[No Abstract] [Full Text] [Related]
9. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
de Mello RA; Madureira P; Carvalho LS; Araújo A; O'Brien M; Popat S
Pharmacogenomics; 2013 Nov; 14(14):1765-77. PubMed ID: 24192124
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
Chua W; Moore MM; Charles KA; Clarke SJ
Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
[TBL] [Abstract][Full Text] [Related]
11. [Clinical development of biomarkers for personalized medicine].
Saito M; Yoshino T
Nihon Rinsho; 2010 Jun; 68(6):1111-6. PubMed ID: 20535964
[TBL] [Abstract][Full Text] [Related]
12. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
13. Adaptive clinical trial design: has its time come?
Nelson NJ
J Natl Cancer Inst; 2010 Aug; 102(16):1217-8. PubMed ID: 20693459
[No Abstract] [Full Text] [Related]
14. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
15. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
16. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
19. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
